Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA)

Topline data for the 15-month primary endpoint are anticipated in the second half of 2027."Compl

Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data

Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercializat

Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Compa

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage bio

Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.50) per share which missed the analy

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natali

Amsterdam, 6 May 2026 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTE

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company develo

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-

US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu

Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company develo

Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision th

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-

Natalie Holles, seasoned industry executive with significant rare disease operational and commercial

HC Wainwright & Co. analyst Andrew S. Fein maintains Aura Biosciences (NASDAQ:AURA) with a Bu

Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their

The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While emp

Aura Biosciences, Inc. (AURA) is looking like an interesting pick from a technical perspective, as t

Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their

The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the sto

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Aura Biosciences (NASDAQ:AURA) wit

Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.37) per share which beat the analyst

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline D

Shares of Aura Biosciences, Inc. (NASDAQ: AURA - Get Free Report) have been assigned an average rati

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the pu

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market tradin

  On Tuesday, 647 companies set new 52-week lows.

  On Wednesday, 220 stocks hit new 52-week lows.

  During Tuesday, 95 stocks hit new 52-week lows.

  Friday's session saw 236 companies set new 52-week lows.

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Mond

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company annou

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.

  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC